Home/Grann Pharmaceuticals/Thomas Lyle Temple
TL

Thomas Lyle Temple

President and CEO

Grann Pharmaceuticals

Grann Pharmaceuticals Pipeline

DrugIndicationPhase
GRN-1Obesity, Non-Alcoholic Fatty Liver Disease (NAFLD)Pre-clinical
CA-1Colorectal AdenocarcinomaPre-clinical
GABA-A Variant (GABRA1/GABRG2)GABA-A Variant DisordersPre-clinical
RTT1Rett SyndromePre-clinical